Nonpharmacologic therapy of ventricular tachycardia.

M. E. Josephson, J. M. Miller, F. E. Marchlinski, A. E. Buxton

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Nonpharmacologic therapies for patients with sustained ventricular tachycardia have been necessitated by the low frequency of drug-responsive patients. These nonpharmacologic therapies include antitachycardia pacemakers, low-energy cardioverters, defibrillators, surgery and, for the present, catheter ablation. Antitachycardia pacing alone should never be used because of the known incidence of acceleration of ventricular tachycardia to ventricular fibrillation. Thus, all electrical devices must include a back-up defibrillator at the very least. The current automatic implantable cardioverter-defibrillator, which has been implanted in over 1000 patients, has been shown to prevent sudden death. Surgery has offered the only method to cure the arrhythmia by removing the arrhythmogenic substrate. Improved surgical techniques with electrophysiologic guidance have an acceptable mortality and a clinical success rate in 80-90% range. Catheter ablation, which is an experimental procedure at this time, offers the promise of a nonsurgical technique to extirpate the ventricular tachycardia substrate.

Original languageEnglish (US)
Pages (from-to)II17-21
JournalClinical cardiology
Volume11
Issue number3 Suppl 2
StatePublished - Mar 1988

Fingerprint

Ventricular Tachycardia
Defibrillators
Catheter Ablation
Implantable Defibrillators
Ventricular Fibrillation
Sudden Death
Cardiac Arrhythmias
Therapeutics
Equipment and Supplies
Mortality
Incidence
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Josephson, M. E., Miller, J. M., Marchlinski, F. E., & Buxton, A. E. (1988). Nonpharmacologic therapy of ventricular tachycardia. Clinical cardiology, 11(3 Suppl 2), II17-21.

Nonpharmacologic therapy of ventricular tachycardia. / Josephson, M. E.; Miller, J. M.; Marchlinski, F. E.; Buxton, A. E.

In: Clinical cardiology, Vol. 11, No. 3 Suppl 2, 03.1988, p. II17-21.

Research output: Contribution to journalArticle

Josephson, ME, Miller, JM, Marchlinski, FE & Buxton, AE 1988, 'Nonpharmacologic therapy of ventricular tachycardia.', Clinical cardiology, vol. 11, no. 3 Suppl 2, pp. II17-21.
Josephson ME, Miller JM, Marchlinski FE, Buxton AE. Nonpharmacologic therapy of ventricular tachycardia. Clinical cardiology. 1988 Mar;11(3 Suppl 2):II17-21.
Josephson, M. E. ; Miller, J. M. ; Marchlinski, F. E. ; Buxton, A. E. / Nonpharmacologic therapy of ventricular tachycardia. In: Clinical cardiology. 1988 ; Vol. 11, No. 3 Suppl 2. pp. II17-21.
@article{51249d0a963044e49766b1add22fdad6,
title = "Nonpharmacologic therapy of ventricular tachycardia.",
abstract = "Nonpharmacologic therapies for patients with sustained ventricular tachycardia have been necessitated by the low frequency of drug-responsive patients. These nonpharmacologic therapies include antitachycardia pacemakers, low-energy cardioverters, defibrillators, surgery and, for the present, catheter ablation. Antitachycardia pacing alone should never be used because of the known incidence of acceleration of ventricular tachycardia to ventricular fibrillation. Thus, all electrical devices must include a back-up defibrillator at the very least. The current automatic implantable cardioverter-defibrillator, which has been implanted in over 1000 patients, has been shown to prevent sudden death. Surgery has offered the only method to cure the arrhythmia by removing the arrhythmogenic substrate. Improved surgical techniques with electrophysiologic guidance have an acceptable mortality and a clinical success rate in 80-90{\%} range. Catheter ablation, which is an experimental procedure at this time, offers the promise of a nonsurgical technique to extirpate the ventricular tachycardia substrate.",
author = "Josephson, {M. E.} and Miller, {J. M.} and Marchlinski, {F. E.} and Buxton, {A. E.}",
year = "1988",
month = "3",
language = "English (US)",
volume = "11",
pages = "II17--21",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "John Wiley and Sons Inc.",
number = "3 Suppl 2",

}

TY - JOUR

T1 - Nonpharmacologic therapy of ventricular tachycardia.

AU - Josephson, M. E.

AU - Miller, J. M.

AU - Marchlinski, F. E.

AU - Buxton, A. E.

PY - 1988/3

Y1 - 1988/3

N2 - Nonpharmacologic therapies for patients with sustained ventricular tachycardia have been necessitated by the low frequency of drug-responsive patients. These nonpharmacologic therapies include antitachycardia pacemakers, low-energy cardioverters, defibrillators, surgery and, for the present, catheter ablation. Antitachycardia pacing alone should never be used because of the known incidence of acceleration of ventricular tachycardia to ventricular fibrillation. Thus, all electrical devices must include a back-up defibrillator at the very least. The current automatic implantable cardioverter-defibrillator, which has been implanted in over 1000 patients, has been shown to prevent sudden death. Surgery has offered the only method to cure the arrhythmia by removing the arrhythmogenic substrate. Improved surgical techniques with electrophysiologic guidance have an acceptable mortality and a clinical success rate in 80-90% range. Catheter ablation, which is an experimental procedure at this time, offers the promise of a nonsurgical technique to extirpate the ventricular tachycardia substrate.

AB - Nonpharmacologic therapies for patients with sustained ventricular tachycardia have been necessitated by the low frequency of drug-responsive patients. These nonpharmacologic therapies include antitachycardia pacemakers, low-energy cardioverters, defibrillators, surgery and, for the present, catheter ablation. Antitachycardia pacing alone should never be used because of the known incidence of acceleration of ventricular tachycardia to ventricular fibrillation. Thus, all electrical devices must include a back-up defibrillator at the very least. The current automatic implantable cardioverter-defibrillator, which has been implanted in over 1000 patients, has been shown to prevent sudden death. Surgery has offered the only method to cure the arrhythmia by removing the arrhythmogenic substrate. Improved surgical techniques with electrophysiologic guidance have an acceptable mortality and a clinical success rate in 80-90% range. Catheter ablation, which is an experimental procedure at this time, offers the promise of a nonsurgical technique to extirpate the ventricular tachycardia substrate.

UR - http://www.scopus.com/inward/record.url?scp=0023967222&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023967222&partnerID=8YFLogxK

M3 - Article

C2 - 3271190

AN - SCOPUS:0023967222

VL - 11

SP - II17-21

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

IS - 3 Suppl 2

ER -